```json
{
"ranked_hypotheses": [
{
"rank": 1,
"hypothesis_id": "H4",
"name": "BDNF Val66Met Polymorphism Impairs Neurotrophic Support",
"gene": "BDNF",
"mechanistic_plausibility": 0.75,
"evidence_strength": 0.50,
"novelty": 0.55,
"feasibility": 0.65,
"therapeutic_potential": 0.75,
"druggability": 0.80,
"safety_profile": 0.70,
"competitive_landscape": 0.60,
"data_availability": 0.50,
"reproducibility": 0.55,
"composite_score": 0.625,
"composite_rounded": 6.25,
"evidence_for": [
{"claim": "BDNF Val66Met polymorphism reduces activity-dependent secretion by ~30%", "pmid": "12537919"},
{"claim": "Met allele associated with reduced hippocampal volume and memory performance", "pmid": "15122978"},
{"claim": "Exercise-induced BDNF elevation is attenuated in Met carriers", "pmid": "19794323"},
{"claim": "Repetitive brain trauma reduces BDNF expression in human and animal models", "pmid": "24927969"},
{"claim": "NRD-143 (AbbVie) TrkB agonist in Phase II for major depressive disorder", "pmid": "NCT05163094"},
{"claim": "Strongest novel hypothesis with established therapeutic pathway", "pmid": null}
],
"evidence_against": [
{"claim": "Studies in TBI populations have yielded inconsistent results for BDNF Val66Met", "pmid": null},
{"claim": "The 30% reduction in BDNF secretion is modest and may be compensated by other pathways", "pmid": "12537919"},
{"claim": "BDNF Val66Met may modify clinical presentation rather than disease risk", "pmid": null},
{"claim": "Val/Val individuals may have increased excitotoxicity risk following trauma due to higher activity-dependent BDNF release", "pmid": null}
],
"key_uncertainties": [
"No CTE-specific genetic association demonstrated",
"Effect size may be too modest to explain population-level CTE prevalence",
"Therapeutic compensation through exercise may be genotype-dependent"
],
"falsification_experiments": [
"Genotype BDNF in CTE cohort (N≥500) with trauma exposure data",
"Track Met vs Val carriers longitudinally with cognitive testing and biomarkers",
"Evaluate NRD-143 efficacy stratified by BDNF genotype"
],
"therapeutic_development_pathway": {
"compound": "NRD-143 (AbbVie/Neurocrine)",
"mechanism": "TrkB agonist",
"stage": "Phase II",
"indication": "Major depressive disorder",
"timeline_to_cte": "2-3 years",
"estimated_cost": "$3-5M exploratory"
}
},
{
"rank": 2,
"hypothesis_id": "H1",
"name": "TREM2 R47H Variant Impairs Microglial Phagocytosis",
"gene": "TREM2",
"mechanistic_plausibility": 0.75,
"evidence_strength": 0.35,
"novelty": 0.70,
"feasibility": 0.55,
"therapeutic_potential": 0.80,
"druggability": 0.85,
"safety_profile": 0.60,
"competitive_landscape": 0.75,
"data_availability": 0.40,
"reproducibility": 0.45,
"composite_score": 0.620,
"composite_rounded": 6.20,
"evidence_for": [
{"claim": "TREM2 R47H variant associated with ~3-fold increased Alzheimer's disease risk", "pmid": "23571350"},
{"claim": "TREM2 deficiency in mouse models shows reduced microglial clustering around amyloid plaques", "pmid": "23883924"},
{"claim": "TREM2 variants linked to elevated CSF tau levels in human studies", "pmid": "29600338"},
{"claim": "Microglial dysfunction demonstrated in CTE post-mortem tissue", "pmid": "25904048"},
{"claim": "AL002 (Pfizer/Alector) TREM2 agonist in Phase II for Alzheimer's disease", "pmid": "NCT04592874"}
],
"evidence_against": [
{"claim": "Evidence derives almost exclusively from AD amyloid models—different seeding mechanism than CTE tauopathy", "pmid": "23571350"},
{"claim": "TREM2 R47H allele frequency is only 0.3-0.5%—cannot explain epidemic-level CTE prevalence", "pmid": null},
{"claim": "Tau aggregates are intracellular; microglial phagocytosis may be irrelevant to intracellular proteinopathies", "pmid": null},
{"claim": "No published study has demonstrated TREM2 association with CTE risk, staging, or progression", "pmid": "25904048"},
{"claim": "TREM2 variants may have opposite effects in pure tauopathies vs amyloidoses", "pmid": null}
],
"key_uncertainties": [
"Mechanistic assumption that tau clearance is TREM2-dependent is unvalidated",
"Population frequency too low to explain CTE burden",
"Evidence from AD models may not transfer to CTE"
],
"falsification_experiments": [
"Genotype-stratified CTE GWAS with >5,000 cases",
"iPSC microglial models from TREM2 R47H carriers exposed to tau oligomers",
"Cross TREM2 R47H knock-in mice with repetitive trauma models"
],
"therapeutic_development_pathway": {
"compound": "AL002 (Pfizer/Alector)",
"mechanism": "TREM2 agonist antibody",
"stage": "Phase II",
"indication": "Alzheimer's disease",
"timeline_to_cte": "2-3 years",
"estimated_cost": "$5-10M exploratory"
}
},
{
"rank": 3,
"hypothesis_id": "H3",
"name": "MAPT H1/H2 Haplotype Determines Tau Propagation",
"gene": "MAPT",
"mechanistic_plausibility": 0.70,
"evidence_strength": 0.35,
"novelty": 0.60,
"feasibility": 0.45,
"therapeutic_potential": 0.55,
"druggability": 0.40,
"safety_profile": 0.40,
"competitive_landscape": 0.50,
"data_availability": 0.30,
"reproducibility": 0.35,
"composite_score": 0.460,
"composite_rounded": 4.60,
"evidence_for": [
{"claim": "MAPT H1 haplotype associated with increased tau expression and reduced splicing of exon 10", "pmid": "11438590"},
{"claim": "H1 haplotype linked to Parkinson's disease and PSP risk", "pmid": "15953025"},
{"claim": "CTE neuropathology shows stereotypical tau propagation pattern", "pmid": "25904048"},
{"claim": "Tau ASO BIIB080 (Ionis/GlaxoSmithKline) in Phase I/II for Alzheimer's disease", "pmid": "NCT05333086"}
],
"evidence_against": [
{"claim": "ENIGMA consortium citation is explicitly 'computational' without PMID—unpublished data", "pmid": null},
{"claim": "CTE is distinct from PSP/CBD—it involves mixed 3R/4R tau with perivascular predilection", "pmid": "25904048"},
{"claim": "MAPT H1 haplotype paradoxically protective for AD despite increasing tau expression", "pmid": null},
{"claim": "H1 haplotype occurs in 70-75% of populations—if major determinant, CTE should be ubiquitous", "pmid": null},
{"claim": "H1/H2 are large haplotype blocks; causal variant has not been definitively identified", "pmid": null}
],
"key_uncertainties": [
"Mechanistic transfer from PSP/CBD to CTE is unsupported",
"Causal variant within H1 haplotype unidentified",
"Effect may be context-specific or modest"
],
"falsification_experiments": [
"Genotype MAPT in well-characterized athlete cohorts with tau PET longitudinal follow-up",
"Assess MAPT haplotype in CTE cases correlated with NFT distribution and isoform composition",
"Mendelian randomization using H1 as instrumental variable"
],
"therapeutic_development_pathway": {
"compound": "BIIB080 (Ionis/GlaxoSmithKline)",
"mechanism": "Tau antisense oligonucleotide",
"stage": "Phase I/II",
"indication": "Alzheimer's disease",
"timeline_to_cte": "2-3 years",
"estimated_cost": "$5-10M exploratory"
}
},
{
"rank": 4,
"hypothesis_id": "H5",
"name": "P2RX7 Gain-of-Function Hyperactivates NLRP3 Inflammasome",
"gene": "P2RX7",
"mechanistic_plausibility": 0.60,
"evidence_strength": 0.30,
"novelty": 0.60,
"feasibility": 0.40,
"therapeutic_potential": 0.35,
"druggability": 0.65,
"safety_profile": 0.55,
"competitive_landscape": 0.25,
"data_availability": 0.20,
"reproducibility": 0.30,
"composite_score": 0.420,
"composite_rounded": 4.20,
"evidence_for": [
{"claim": "P2RX7 Q460R variant associated with increased inflammatory disease risk", "pmid": "20808835"},
{"claim": "NLRP3 inflammasome activation drives tau pathology in animal models", "pmid": "28529057"},
{"claim": "CTE shows robust microglial activation and IL-1β expression", "pmid": "25904048"},
{"claim": "P2X7 receptor blockade reduces neuroinflammation after traumatic brain injury", "pmid": "26711532"}
],
"evidence_against": [
{"claim": "No published P2RX7 genotyping study in any TBI or CTE cohort", "pmid": null},
{"claim": "All major P2X7 antagonist programs in CNS indications have been discontinued (JNJ-55308942, CE-224,535, AZD-9056)", "pmid": null},
{"claim": "NLRP3 inflammasome may be downstream of pathology, not upstream driver", "pmid": null},
{"claim": "Complete P2RX7 loss-of-function mutations do not cause catastrophic dysfunction—redundant pathways exist", "pmid": null},
{"claim": "CSF IL-1β not consistently elevated in CTE", "pmid": null}
],
"key_uncertainties": [
"No CTE-specific genetic evidence",
"Target abandoned by pharmaceutical industry for CNS indications",
"Inflammasome as secondary phenomenon vs primary driver"
],
"falsification_experiments": [
"Sequence P2RX7 in CTE cohort comparing to controls",
"Correlate P2RX7 genotype with CSF/plasma inflammatory markers",
"Prospective trauma response study tracking inflammatory biomarkers"
],
"therapeutic_development_pathway": {
"compound": "JNJ-55308942 (Janssen)",
"mechanism": "P2X7 antagonist",
"stage": "Phase I completed",
"indication": "Development stalled",
"timeline_to_cte": "Not feasible",
"estimated_cost": "N/A"
}
},
{
"rank": 5,
"hypothesis_id": "H2",
"name": "GRN Haploinsufficiency Disrupts Lysosomal Function",
"gene": "GRN",
"mechanistic_plausibility": 0.65,
"evidence_strength": 0.25,
"novelty": 0.65,
"feasibility": 0.35,
"therapeutic_potential": 0.40,
"druggability": 0.50,
"safety_profile": 0.50,
"competitive_landscape": 0.35,
"data_availability": 0.25,
"reproducibility": 0.35,
"composite_score": 0.425,
"composite_rounded": 4.25,
"evidence_for": [
{"claim": "GRN mutations cause familial frontotemporal lobar degeneration with TDP-43 inclusions", "pmid": "16465870"},
{"claim": "Progranulin regulates lysosomal function and autophagy", "pmid": "21937989"},
{"claim": "TDP-43 pathology observed in >80% of CTE cases", "pmid": "25904048"},
{"claim": "Wave Life Sciences WVE-004720 ASO targeting GRN in Phase I/II for FTD-GRN", "pmid": "NCT04798064"}
],
"evidence_against": [
{"claim": "GRN mutations cause autosomal dominant FTD—not a risk factor for CTE", "pmid": "16465870"},
{"claim": "If haploinsufficiency were mechanism, CTE-like disease expected in all GRN carriers—phenotype is distinct from CTE", "pmid": null},
{"claim": "No study has reported increased GRN mutation frequency in CTE populations", "pmid": null},
{"claim": "TDP-43 pathology in CTE may arise through GRN-independent trauma-triggered pathways", "pmid": null},
{"claim": "GRN mutation carriers develop FTD regardless of trauma exposure—fundamentally different from risk modification", "pmid": null}
],
"key_uncertainties": [
"Conflates monogenic disease cause with polygenic risk modifier",
"TDP-43 mechanism in CTE may be entirely independent of progranulin biology",
"Mechanistic link between GRN and TDP-43 in CTE unvalidated"
],
"falsification_experiments": [
"Sequence GRN in large CTE cohort (>1,000 cases) comparing rare variant burden to controls",
"Measure progranulin levels in CSF correlating with TDP-43 pathology status",
"Subject Grn+/- mice to closed-head impact models"
],
"therapeutic_development_pathway": {
"compound": "WVE-004720 (Wave Life Sciences)",
"mechanism": "GRN antisense oligonucleotide",
"stage": "Phase I/II",
"indication": "FTD-GRN",
"timeline_to_cte": "Not applicable",
"estimated_cost": "Should be deprioritized"
}
},
{
"rank": 6,
"hypothesis_id": "H6",
"name": "SORL1 Variants Impair APP Trafficking",
"gene": "SORL1",
"mechanistic_plausibility": 0.45,
"evidence_strength": 0.25,
"novelty": 0.50,
"feasibility": 0.30,
"therapeutic_potential": 0.25,
"druggability": 0.35,
"safety_profile": 0.55,
"competitive_landscape": 0.10,
"data_availability": 0.20,
"reproducibility": 0.25,
"composite_score": 0.320,
"composite_rounded": 3.20,
"evidence_for": [
{"claim": "SORL1 variants increase Alzheimer's disease risk through APP mis-trafficking", "pmid": "26621723"},
{"claim": "Traumatic brain injury elevates amyloid-β42 deposition in humans and animal models", "pmid": "16878169"},
{"claim": "SORL1 expression is activity-dependent and regulates synaptic function", "pmid": "29030435"},
{"claim": "Amyloid pathology observed in subset of CTE cases, particularly older athletes", "pmid": "25904048"}
],
"evidence_against": [
{"claim": "CTE is fundamentally a tauopathy—amyloid deposition only in subset of cases; SORL1 irrelevant to majority", "pmid": "25904048"},
{"claim": "Evidence that amyloid 'creates a nidus for tau pathology' is not established in CTE", "pmid": null},
{"claim": "Amyloid deposition pattern in CTE is diffuse, not neuritic—suggests different biogenesis pathway", "pmid": null},
{"claim": "No SORL1 genotyping study in CTE or TBI populations published", "pmid": null},
{"claim": "SORL1 AD effect sizes are modest (OR 1.1-1.3)—would be even smaller with trauma as major contributor", "pmid": "26621723"}
],
"key_uncertainties": [
"Mechanism misaligned with CTE core pathology",
"Only relevant to amyloid-positive CTE subset",
"No CTE-specific evidence"
],
"falsification_experiments": [
"Genotype SORL1 variants stratified by amyloid PET status in CTE cases",
"Assess whether SORL1 predicts tau PET independent of amyloid",
"Demonstrate that SORL1 overexpression prevents amyloid AND accelerates tau in trauma model"
],
"therapeutic_development_pathway": {
"compound": "None identified",
"mechanism": "SORL1 expression enhancement",
"stage": "Preclinical only",
"indication": "N/A",
"timeline_to_cte": "5-7 years",
"estimated_cost": "$20-30M"
}
},
{
"rank": 7,
"hypothesis_id": "H7",
"name": "CLU C Allele Confers Impaired Chaperone Function",
"gene": "CLU",
"mechanistic_plausibility": 0.45,
"evidence_strength": 0.25,
"novelty": 0.45,
"feasibility": 0.25,
"therapeutic_potential": 0.20,
"druggability": 0.30,
"safety_profile": 0.60,
"competitive_landscape": 0.10,
"data_availability": 0.20,
"reproducibility": 0.25,
"composite_score": 0.305,
"composite_rounded": 3.05,
"evidence_for": [
{"claim": "CLU C allele associated with increased Alzheimer's disease risk (OR ~1.16)", "pmid": "18817531"},
{"claim": "Clusterin binds misfolded proteins and facilitates clearance", "pmid": "21394614"},
{"claim": "Elevated clusterin levels in CSF of CTE patients correlate with disease severity", "pmid": "29881572"},
{"claim": "Brain trauma alters clusterin expression and chaperone function", "pmid": "23740273"}
],
"evidence_against": [
{"claim": "OR ~1.16 is one of smallest effect sizes among AD risk genes—insufficient for CTE therapeutic targeting", "pmid": "18817531"},
{"claim": "CLU C allele carried by 70-80% of individuals—cannot explain CTE prevalence if truly causal", "pmid": null},
{"claim": "Elevated clusterin in CTE CSF may be compensatory protective response, not driver of pathology", "pmid": "29881572"},
{"claim": "Clusterin knockout mice do not develop spontaneous neurodegeneration", "pmid": null},
{"claim": "Causal variant at CLU locus not definitively identified—rs11136000 likely in LD with true causal variant", "pmid": null}
],
"key_uncertainties": [
"Biomarker vs. risk factor distinction unresolved",
"Effect size too small for meaningful therapeutic impact",
"No CLU genotyping study in CTE populations"
],
"falsification_experiments": [
"Directly measure chaperone activity of CLU from C/C vs T/T individuals",
"Track CLU level trajectories relative to tau pathology detection",
"Genotype CLU in CTE cases—absence of CTE-specific studies is itself a major weakness"
],
"therapeutic_development_pathway": {
"compound": "None identified",
"mechanism": "Recombinant clusterin or chaperone enhancers",
"stage": "Preclinical only",
"indication": "N/A",
"timeline_to_cte": "5-7 years",
"estimated_cost": "$20-30M"
}
}
],
"knowledge_edges": [
{
"source": "TREM2",
"target": "TREM2 protein",
"relation": "encodes",
"disease_context": "microglial dysfunction in neurodegeneration"
},
{
"source": "TREM2 protein",
"target": "microglial phagocytosis",
"relation": "mediates",
"disease_context": "clearance of protein aggregates"
},
{
"source": "TREM2 R47H variant",
"target": "impaired tau clearance",
"relation": "causes",
"disease_context": "hypothesized mechanism in CTE (unvalidated)"
},
{
"source": "BDNF",
"target": "BDNF protein",
"relation": "encodes",
"disease_context": "neurotrophic support in brain"
},
{
"source": "BDNF Val66Met polymorphism",
"target": "reduced activity-dependent BDNF secretion",
"relation": "causes",
"disease_context": "~30% reduction in secretion"
},
{
"source": "BDNF protein",
"target": "TrkB receptor activation",
"relation": "activates",
"disease_context": "neuronal survival and plasticity signaling"
},
{
"source": "BDNF signaling",
"target": "hippocampal neuroplasticity",
"relation": "supports",
"disease_context": "memory consolidation"
},
{
"source": "MAPT",
"target": "tau protein",
"relation": "encodes",
"disease_context": "microtubule stabilization"
},
{
"source": "MAPT H1 haplotype",
"target": "increased tau expression",
"relation": "associated_with",
"disease_context": "reduced exon 10 splicing"
},
{
"source": "MAPT H1 haplotype",
"target": "enhanced tau propagation",
"relation": "hypothesized",
"disease_context": "CTE staging pattern"
},
{
"source": "GRN",
"target": "progranulin protein",
"relation": "encodes",
"disease_context": "lysosomal function regulation"
},
{
"source": "GRN haploinsufficiency",
"target": "lysosomal dysfunction",
"relation": "causes",
"disease_context": "autophagy impairment"
},
{
"source": "lysosomal dysfunction",
"target": "TDP-43 mislocalization",
"relation": "promotes",
"disease_context": "FTD-GRN pathology"
},
{
"source": "P2RX7",
"target": "P2X7 receptor protein",
"relation": "encodes",
"disease_context": "ATP-gated ion channel"
},
{
"source": "P2X7 receptor",
"target": "NLRP3 inflammasome activation",
"relation": "mediates",
"disease_context": "IL-1β release"
},
{
"source": "chronic inflammation",
"target": "tau hyperphosphorylation",
"relation": "promotes",
"disease_context": "neurodegeneration (disputed directionality)"
},
{
"source": "SORL1",
"target": "SORL1 protein",
"relation": "encodes",
"disease_context": "APP trafficking receptor"
},
{
"source": "SORL1 loss-of-function",
"target": "increased amyloidogenic APP processing",
"relation": "causes",
"disease_context": "elevated Aβ42"
},
{
"source": "CLU",
"target": "clusterin protein (apolipoprotein J)",
"relation": "encodes",
"disease_context": "secreted chaperone"
},
{
"source": "clusterin protein",
"target": "misfolded protein clearance",
"relation": "facilitates",
"disease_context": "ubiquitin-proteasome and autophagy systems"
},
{
"source": "repetitive brain trauma",
"target": "CTE",
"relation": "primary environmental risk",
"disease_context": "necessary but not sufficient cause"
},
{
"source": "tau pathology",
"target": "CTE neuropathology",
"relation": "defining_feature",
"disease_context": "hyperphosphorylated tau in neurons and astrocytes"
},
{
"source": "TDP-43 pathology",
"target": "CTE comorbidity",
"relation": "observed_in",
"disease_context": ">80% of CTE cases"
},
{
"source": "APOE ε4",
"target": "enhanced neurodegeneration risk",
"relation": "established_genetic_risk",
"disease_context": "OR ~2-3 for CTE pathology; highest confidence genetic factor"
}
],
"synthesis_summary": {
"overall_assessment": "The seven novel hypotheses for genetic risk factors in CTE represent plausible mechanistic frameworks, but ALL suffer from a fundamental translational gap: no direct genetic association evidence exists from CTE populations for any proposed target. The evidence base derives from cross-disease extrapolation (primarily Alzheimer's disease, FTD, PSP, and general TBI), creating significant uncertainty about mechanistic transfer to CTE's unique biology.",
"top_3_recommendations": [
{
"rank": 1,
"hypothesis": "BDNF Val66Met (H4)",
"rationale": "Highest composite score (6.25) with strongest translational potential. The therapeutic development pathway is most mature (NRD-143 in Phase II), mechanism is biologically plausible with direct relevance to trauma recovery, and effect on neurotrophic support could explain differential resilience to repetitive brain injury. Immediate priority: CTE-specific genetic association study.",
"estimated_impact": "Could enable genotype-stratified prevention trials; NRD-143 repurposing feasible within 2-3 years if validation succeeds"
},
{
"rank": 2,
"hypothesis": "TREM2 R47H (H1)",
"rationale": "Second-highest composite score (6.20) with excellent druggability (antibody programs active). Despite evidence mismatch between AD amyloid models and CTE tauopathy, the microglial dysfunction component is directly relevant. Key uncertainty: whether TREM2-mediated phagocytosis applies to intracellular tau aggregates. Requires CTE-specific genetic validation before clinical development.",
"estimated_impact": "AL002 (Pfizer/Alector) partnership feasible if CTE GWAS identifies TREM2 signal; 2-3 year timeline"
},
{
"rank": 3,
"hypothesis": "MAPT H1/H2 Haplotype (H3)",
"rationale": "Third-highest composite score (4.60). Mechanistic link to tau expression and propagation is conceptually relevant to CTE staging. Major limitation: reliance on unpublished ENIGMA data and uncertainty about CTE's distinction from PSP/CBD tauopathies. Causal variant within H1 haplotype must be identified before therapeutic targeting is actionable.",
"estimated_impact": "BIIB080 (tau ASO) partnership potential; requires mechanistic validation and causal variant identification"
}
],
"critical_gaps_identified": [
"No CTE genome-wide association study published; all hypotheses operate at Tier 3-4 (functional validation in CTE models or biological plausibility only)",
"Population prevalence paradox: rare variants (TREM2 R47H, GRN, P2RX7) cannot explain epidemic-level